RESEARCH ARTICLE

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1

Johannes Ettl1*, Evelyn Klein1, Alexander Hapfelmeier2, Kirsten Grosse Lackmann1, Stefan Paepke1, Christoph Petry3, Katja Specht4, Laura Wolff1, Heinz Höfler4, Marion Kiechle1

1 Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München, Munich, Germany, 2 Institute of Medical Statistics and Epidemiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany, 3 Sividon Diagnostics GmbH, Cologne, Germany, 4 Institute of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

* johannes.ettl@tum.de

Abstract

Background
Adjuvant therapy decisions in early breast cancer are based on accurate risk assessment. Urokinase plasminogen activator (uPA) and plaminogen activator inhibitor-1 (PAI-1) have been the first biomarkers in hormone receptor (HR) positive breast cancer to reach highest level of evidence. The EndoPredict test (EPclin) combines gene expression information with nodal status and tumor size. The aim of this prospective study was to compare uPA/PAI-1 and EPclin as prognostic biomarkers with regard to feasibility, risk stratification and impact on adjuvant therapy recommendation.

Materials and method
395 patients with HR positive, HER2 negative, intermediate risk breast cancer were enrolled. Relations and concordance of histologic grading as well as EPclin and uPA/PAI-1 values were assessed by Spearman’s rank correlation coefficient and Cohen’s Kappa. To compare decision impact of EPclin and uPA/PAI-1 three independent case discussions were held: One with known uPA/PAI-1 and EPclin results, one blinded to EPclin alone and another one blinded to both EPclin and uPA/PAI-1.

Results
EPclin could be determined in all 395 (100%), uPA/PAI-1 in 190 (48%) of the tumor samples. EPclin allocated 250 patients (63%) to the low-risk group and 145 patients (37%) to the high-risk group, whereas uPA/PAI-1 allocated 88 patients (46%) to the low-risk group and 102 patients (54%) to the high-risk group. In 59% of cases, both tests showed concordant
results. EPclin resulted more frequently in a change of therapy recommendation than the uPA/PAI-1 test (46% vs 24%). Recommendation of adjuvant chemotherapy (CTX) was abandoned twice as often by EPclin (45%) compared to uPA/PAI-1 (22%).

Conclusion
In this first prospective comparison of EPclin and uPA/PAI-1 we found, that EPclin is superior to uPA/PAI-1 with respect to feasibility and decision impact. This leads to substantial avoidance of adjuvant CTX in endocrine-sensitive, HER2-negative breast cancer. Data collection for patients’ clinical outcome is ongoing.

Introduction
Patients diagnosed with early breast cancer are faced with life-long risk of distant metastases. Nevertheless, along with intensified early detection and optimized adjuvant systemic therapies, an improvement of disease-free and overall survival could be observed in recent years [1]. In the overall patient population, adjuvant chemotherapy (CTX) shows a significant therapeutic benefit [2]. However, focusing on the population of patients with hormone receptor (HR) positive disease, it becomes clear that there are patient subgroups that will be cured just by adjuvant endocrine therapy without adjuvant CTX. Validated prognostic markers are required to identify this subgroup. Recognized conventional prognostic markers with proven relevance are tumor size, nodal status, grading, histological subtype and age. Still, these biomarkers are insufficient to obtain adequate risk stratification in a HR-positive, HER2-negative population. Therefore, a number of additional new molecular biomarkers has been developed and validated which allow a better defined distinction between "high" and "low" risk of metastases.

The urokinase plasminogen activator (uPA) system plays an important role in the process of tumor cell invasion and metastasis [3]. As early as 1988, it was demonstrated that elevated levels of uPA in tumor tissue of breast cancer patients are associated with poor prognosis [4]. Shortly after, it was shown for the first time that also high concentrations of plasminogen activator inhibitor-1 (PAI-1) are associated with a worse clinical course [5]. Observations in various animal models showed that uPA is a crucial factor in the process of tumor progression [6]. uPA and PAI-1 have been investigated as prognostic factors in early breast cancer in many retrospective and prospective, independent clinical trials ever since. The determination of uPA and PAI-1 concentration in tumor tissue by enzyme-linked immunosorbent assay (ELISA) is the first prospectively validated biomarker in early breast cancer with level of evidence (LOE) 1A, following the systematics of Hayes et al [7]. As part of the multicenter Chemo-N0-trial (n = 647, 12 centers), it was shown that in N0 patients the uPA/PAI-1 test can identify a group of patients that can be spared adjuvant CTX [8]. Based on these results and on the data from a comprehensive meta-analysis (n = 8377) conducted by the European Organisation for Research and Treatment of Cancer (EORTC) [9], uPA/PAI-1 has been recommended as biomarker for risk stratification and therapeutic decision making in node-negative breast cancer in the guidelines of the American Society of Clinical Oncology (ASCO) since 2007 as well as of the German Society of Gynecological Oncology (AGO) since 2006 [10] [11]. Despite convincing data and a commercially available ELISA assay for uPA/PAI-1, the proteolytic factors are not generally used as biomarkers for prognostic assessment of early breast cancer in clinical practice. Also uPA/PAI-1 has never been included as a prognostic factor in the recommendations of the St. Gallen Consensus Conference. One reason for this may be that uPA/PAI-1...
determination is logistically demanding since the test can be performed only on fresh tissue [12].

Risk stratification based on gene expression analysis was described for the first time by Perou and colleagues with the introduction of the intrinsic subtypes in the molecular pathology of breast cancer [13]. It was shown that various intrinsic subtypes are associated with a different prognosis of the disease, which affects the overall and relapse-free survival [14]. Based on these findings, several commercially available gene expression tests have been developed. The tests allow identifying a group of patients whose prognosis under adjuvant endocrine therapy is so good that adjuvant CTX can be abandoned. For these patients the expected benefits of CTX would be smaller than the risks conferred by CTX. A number of these multiparameter assays has been added to the therapy recommendation of the St. Gallen International Expert Consensus, including the EndoPredict test (EPclin) [15].

EPclin is a RNA-based 11-gene expression test which can be carried out on formalin-fixed, paraffin-embedded (FFPE) tumor tissue. It allows the prediction of the likelihood of distant metastases in patients with ER-positive, HER2-negative breast cancer. The test has been validated in four large randomized phase III studies (ABCSG-6: n = 378; ABCSG-8: n = 1324; GEICAM9906: n = 555 and ATAC: n = 928) and thus has the evidence level LOE IB according to Simon et al [7]. EPclin was the first gene expression test to demonstrate that it provides additional prognostic information on top of grading, tumor size, nodal status and ki67 in a cohort of endocrine-sensitive breast cancer patients [16]. More recent data show that EPclin also predicts late metastasis and local recurrence in hormone receptor-positive breast cancer [17,18].

The aim of this prospective study was to compare the two prognostic tests uPA/PAI-1 and EPclin with regard to feasibility, risk stratification, and impact of the test result on adjuvant therapy recommendation in hormone-sensitive, HER2 negative breast cancer with 0–3 positive lymph nodes.

Materials and methods

395 consecutive female patients with primary invasive estrogen receptor (ER) positive, HER2 negative, intermediate risk (as defined by the Interdisciplinary S3-Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer [19]) breast cancer were enrolled in the study. All patients underwent primary therapy at the interdisciplinary breast center of Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Regarding treatment recommendations case discussions were held during an interdisciplinary tumor conference for all patients. The results of the uPA/PAI-1 test and the EPclin were known to the tumor conference. Additionally a second and third conference was held: One conference accounted for all patient information but the EPclin and uPA/PAI-1 results, another conference was blinded to the EPclin result but was aware of uPA/PAI-1 results. Consequently three separate treatment recommendations were generated.

Assessment of the EPclin score

The EPclin score is a second generation genomic expression assay calculating risk of recurrence in primary HR positive, HER2 negative breast cancer. A thorough report of the key facts of the EPclin score is reported elsewhere [16]. In sum, the EndoPredict assay (Sividon Diagnostics GmbH, Cologne, Germany) analyses the expression levels of eight genes of interest (BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1, MGP and STC2), as well as three normalization genes (CALM2, OAZ1, RPL37A). For the risk score calculation RNA levels assessed by quantitative reverse transcription PCR (RT-qPCR) in FFPE tumor tissue were used. As
published previously the PCR results can be translated into a quantitative risk score using a web-based implementation of the EndoPredict algorithm [20]. The RNA score is finally combined with the clinicopathological parameters tumor size and lymph node involvement which leads to the final EPclin test result. The software for the required computations is now CE-marked and available under: https://www2.endopredict.com/EPReportGenerator. The validated cut-offs for EndoPredict score and EPclin score for discrimination into low and high risk of distant recurrence are 5 and 3.3 respectively [16].

Assessment of uPA and PAI-1 levels

Directly after surgery the tumor tissue was transferred to the pathologist laboratory for further processing into tumor extracts as described previously [21]. In brief, in order to determine uPA and PAI-1 levels Femtelle ELISA assay (Sekisui Diagnostics LLC, formerly American Diagnostic Inc., Stamford, CT, USA) and Pierce protein assay (Rockford, IL) were used. The validated cutoff points were utilized: patients with low concentrations of uPA (< 3 ng/mg of protein) and PAI-1 (<14 ng/mg of protein) were categorized as low risk; patients with high levels of uPA (≥ 3 ng/mg of protein) or/and PAI-1 (≥14 ng/mg of protein) were categorized as high risk.

Statistics

The distribution of quantitative and qualitative data is presented by descriptive statistics such as median (range) and absolute (relative) frequencies, respectively. Corresponding hypothesis testing for group comparisons was performed by Mann-Whitney-U tests and Fisher’s exact test. Relations and concordance of histologic parameters as well as EPclin and uPA/PAI-1 values and test results were assessed by Spearman’s rank correlation coefficient and Cohen’s Kappa. Disagreements of classifications were investigated by McNemar’s tests / exact binomial tests. All statistical tests were conducted on exploratory, two-sided 5% significance levels using R 3.2.0 [22].

Ethics statement

This observational study was approved by the ethics committee of the faculty of medicine at Klinikum rechts der Isar, Technische Universität München. The need for informed consent was waived.

Results

Study population

A total of 395 patients were enrolled between March 2012 and March 2015. The median age of the patients was 59 (29–88) years. Exact tumor characteristics are listed in Table 1.

Test results EPclin and uPA/PAI-1

The EPclin test was carried out on all 395 tumor samples. The test result allocated 250 patients (63%) in the low-risk group and 145 patients (37%) in the high-risk group. uPA/PAI-1 was evaluated in 190 (48%) of the tumor samples. The uPA/PAI-1 test allocated 88 patients (46%) in the low-risk group and 102 patients (54%) in the high-risk group (Fig 1).
Correlation between test results and histological grading

Fig 2 shows the distribution of the test results as a function of conventional histopathological parameter of grading. Both tests show a significant but weak correlation, whereby the EPclin class (Fig 2A) shows a stronger correlation with grading than the protease class (Fig 2B) (Spearman’s correlation rho = 0.32; p < 0.001 vs. rho = 0.17; p = 0.021).

Correlation between EPclin score and level of uPA/PAI-1

Fig 3 shows that comparison of EPclin scores with corresponding u-PA values results in a moderate correlation between EPclin and uPA.

In contrast, only very weak correlation exists between EPclin and PAI-1 (Fig 4).

Moreover, a dichotomization based on established threshold values (EPclin values: 3.3, uPA: 3, PAI-1: 14) shows a moderate or weak concordance of the classification into low-risk and high-risk groups (Figs 3 and 4; Cohens’s kappa κ = 0.313; p < 0.001 vs. κ = 0.176; p = 0.066).

Comparison of risk classification by EPclin and uPA/PAI-1

In 190 cases of the whole study population both tests could be performed. Table 2 shows comparison between risk classification by EPclin and by uPA/PAI-1.

In 59% of cases, both tests resulted in allocation into the same group. A dissimilar risk allocation resulted in 41% of cases, which tended to be more frequent in the group with high uPA/PAI-1 levels (26%) (McNemar’s test, p = 0.009).
Table 3 shows the frequencies of change in therapy recommendation (decision impact) by the uPA/PAI-1 results set against the decision impact by the EPclin test.

The recommendations coincide in 123 (65%) of 190 cases. They differ in 67 (35%) of 190 cases, whereby at different results, the therapy recommendation is significantly more frequently affected by EPclin than by uPA/PAI-1, namely in 54 (28%) cases versus 13 (7%) cases ($p < 0.001$, exact binomial test). In cases of disparate recommendations, CTX was not recommended by uPA/PAI-1 in 10 (77%) of 13 cases and by EPclin in 53 (98%) of 54 cases ($p = 0.021$, Fisher’s exact test).

Fig 5 shows decision impact of EPclin test results in the overall population of 395 patients. With results of the uPA/PAI-1 test on 190 patients taken into account, the EPclin test resulted in a change in therapy recommendation in 170 patients (41%), favoring avoidance of CTX 150 times (38%) and its addition 20 times (5%).

Fig 5 shows decision impact of EPclin test results in the overall population of 395 patients. With results of the uPA/PAI-1 test on 190 patients taken into account, the EPclin test resulted in a change in therapy recommendation in 170 patients (41%), favoring avoidance of CTX 150 times (38%) and its addition 20 times (5%).

Fig 6 refers only to the 190 patients in whom both the EPclin test and uPA/PAI-1 test were carried out, thus allowing direct comparison of the decision impact of EPclin and uPA/PAI-1.

The uPA/PAI-1 test resulted in a change in therapy recommendation in 46 patients (24%), favoring avoidance of CTX 42 times (22%) and its addition 4 times (2%) (Fig 6A). In contrast, the EPclin test resulted in a change in therapy recommendation in 87 patients (46%), favoring avoidance of CTX 85 times (45%) and its addition 2 times (1%) (Fig 6B).
In this study, two standardized and validated prognostic tests—EPclin and uPA/PAI-1—were prospectively compared for the first time with respect to feasibility, risk stratification and influence on adjuvant therapy recommendation in endocrine sensitive, HER2-negative early breast cancer.

EPclin resulted significantly more frequently in a change of therapy recommendation than the uPA/PAI-1 test (46% vs. 24%). The change was in almost all cases abstention from recommendation of adjuvant CTX (45% vs. 22%) so that recommendation of adjuvant CTX was abandoned twice as often by EPclin compared to the uPA/PAI-1 test. EPclin is therefore clearly superior to the uPA/PAI-1 test with respect to possible avoidance of adjuvant CTX. This is of paramount importance in clinical practice as implementation of EPclin could reduce overtreatment and associated CTX-induced toxicities in the individual patient to a greater extent than uPA/PAI-1. Moreover substantial treatment-related healthcare costs could be further reduced. Blank et al analyzed the health economic effect of EPclin in the population of 1619 patients of the ABCSG 6/8 trials and determined that EPclin-based risk stratification presents a cost-effective tool for reducing CTX-associated costs [23].

EPclin and uPA/PAI-1 have been validated for risk stratification of patients with endocrine sensitive early breast cancer and have been used already for some time in clinical routine. The risk stratification performed in the context of the present study by uPA/PAI-1 (46% low risk, 54% high risk) and EPclin (63% low risk, 37% high risk) is consistent with published data from other retrospective, monocentric surveys; recently, Kolben et al reported about 381 intermediate-risk patients, of which 45% were uPA/PAI-1 low risk and 55% were uPA/PAI-1 high risk [24]. Müller et al report a EPclin low-risk group of 48% in a cohort of 167 defined tumors in which smaller tumors (pT1a/b) were under-represented compared to the present study [20].
Schlake et al report about a cohort of 82 patients in which EPclin lead to a low-risk classification in 68% of the cases [25].

Our study provides for the first time data for direct comparison of risk stratification by uPA/PAI-1 and EPclin: In 77 (41%) of 190 cases in which both tests were performed, the results were discrepant, i.e., different risk allocations resulted depending on the used test result. The discrepancy and the only moderate correlation between the two tests can be explained by the different test characteristics: EPclin determines expression levels of genes associated with tumor cell proliferation and hormone receptor activity at the RNA level. The uPA/PAI-1 assay determines the uPA and PAI-1 content of tumor tissue at the protein level. UPA and PAI-1 are responsible for pericellular mechanisms such as localized proteolysis, cell adhesion and migration [26]. Unlike PAI-1, uPA has been attributed with a proliferation-promoting role, similar to that of a growth factor [27]. This may explain why we could demonstrate a moderate correlation between EP and uPA values (r = 0.385) while EPclin and PAI-1 values correlated only very weakly (r = 0.179). The measured differences in the strength of correlation between EPclin or uPA/PAI-1 and the conventional histopathological prognostic parameter of grading also suggest that the two tests map distinct biological properties of the tumor. It is also likely that inclusion of the clinicopathological parameters tumor size and nodal status provides

![Moderate correlation between EPclin and uPA](https://doi.org/10.1371/journal.pone.0183917.g003)

**Fig 3. Moderate correlation between EPclin and uPA.** Relations are quantified by Spearman’s rank correlation coefficient (r). Allocation to risk classes is indicated by dashed lines. Corresponding concordance is measured by Cohen’s kappa (κ).

https://doi.org/10.1371/journal.pone.0183917.g003
additional prognostic information to the EPclin score, which is disregarded in the uPA/PAI-1 test also contributing to divergent results.

This is not the first time that use of two different prognostic tests on a defined cohort has shown to produce different results in one and the same patient. Even comparison of two

Table 2. Risk classification by EPclin vs. uPA/PAI-1.

|       | uPA/PAI-1 high risk | uPA/PAI-1 low risk |
|-------|---------------------|--------------------|
| EPclin high risk | 52 (27%)            | 27 (15%)           |
| EPclin low risk  | 50 (26%)            | 61 (32%)           |

Table 3. Decision impact by EPclin vs. uPA/PAI-1.

|       | no impact according to uPA/PAI-1 | minus CTX according to uPA/PAI-1 | plus CTX according to uPA/PAI-1 |
|-------|----------------------------------|----------------------------------|----------------------------------|
| no impact according to EPclin | 90 (47%)                         | 10 (5%)                          | 3 (2%)                           |
| minus CTX according to EPclin | 53 (28%)                         | 32 (17%)                         | 0                                |
| plus CTX according to EPclin  | 1 (0.5%)                         | 0                                | 1 (0.5%)                         |
different gene expression tests leads to discrepant test results: Varga et al retrospectively determined the EPclin score in 34 patients for whom an Oncotype DX recurrence score was available. With 76%, only a moderate concordance of the two gene expression tests was demonstrated. The authors attribute this to the different weighting of the various biological properties of the tumor measured at the gene expression level [28].

EPclin was clearly superior to uPA/PAI-1 with regard to feasibility in clinical practice: EPclin could be determined in all 395 tumor samples included in the study. In contrast, uPA/PAI-1 test was performed in only 190 (48%) of the tumor samples. Similar data on limited feasibility of the uPA/PAI-1 test can be found in a French study in which the uPA/PAI-1 test was feasible in only 57% of a total of 285 tumors [29]. In a retrospective study by Müller et al, test feasibility for EPclin was 99%, which is similar to that in our study [20]. The difference in test feasibility in our study is due to the fact that the uPA/PAI-1 test can be performed exclusively on fresh tissue. Tissue for the uPA/PAI-1 test must be collected immediately after surgery as a frozen section. About 50 mg of tumor tissue is required for protein determination, which makes the test often not feasible for small tumors. Furthermore, fresh tissue collection in clinical routine is far more demanding than collection of FFPE tissue samples. In contrast to

---

**Fig 5. Decision impact by EPclin in the overall study population.** Interdisciplinary tumor conference was aware of both EPclin and uPA/PAI-1 results.

https://doi.org/10.1371/journal.pone.0183917.g005
Fig 6. Decision impact by EPclin is stronger compared to decision impact by uPA/PAI-1. (A) Decision impact by uPA/PAI-1. (B) Decision impact by EPclin.

https://doi.org/10.1371/journal.pone.0183917.g006
EPclin, postoperative determination of uPA/PAI-1 in formalin-FFPE tissue is not established for clinical routine yet. EPclin can be determined from a single 5 μm FFPE tissue section.

The novelty of this study is that two different prognostic tests were used prospectively in clinical routine, and that both test results and therapy recommendations were compared with each other. Thus, it could be shown that the existing discrepancy in the test results indeed leads to a significant change in the recommendation of adjuvant therapy. Use of the EPclin test is significantly more likely to result in refraining from adjuvant CTX. Limitations of this study include the unicentric and non-randomized design and the lack of data on the relapse-free survival of the patients. It is of paramount clinical relevance to determine the effect of avoidance of CTX on the prognosis of this patient population. Data on disease-free and metastasis-free survival is being collected prospectively in the course of a follow-up study and will be available in near future.

**Conclusion**

In summary, our study shows that EPclin is superior to uPA/PAI-1 with respect to feasibility and impact on recommendation of adjuvant therapy. Unlike the logistically more demanding uPA/PA-I, EPclin is feasible in routine clinical practice and results in substantial avoidance of adjuvant CTX in endocrine-sensitive, HER2-negative breast cancer. Prospective evaluation of distant relapse-free survival of patients for whom therapy decision has been influenced by EPclin is ongoing.

**Author Contributions**

**Conceptualization:** Johannes Ettl, Evelyn Klein, Stefan Paepke, Christoph Petry, Katja Specht, Marion Kiechle.

**Data curation:** Johannes Ettl, Evelyn Klein, Alexander Hapfelmeier, Katja Specht, Laura Wolff, Marion Kiechle.

**Formal analysis:** Johannes Ettl, Evelyn Klein, Alexander Hapfelmeier, Kirsten Grosse Lackmann, Christoph Petry, Laura Wolff, Marion Kiechle.

**Methodology:** Alexander Hapfelmeier, Katja Specht, Marion Kiechle.

**Project administration:** Johannes Ettl, Christoph Petry, Marion Kiechle.

**Resources:** Kirsten Grosse Lackmann.

**Supervision:** Stefan Paepke, Heinz Höfler, Marion Kiechle.

**Visualization:** Alexander Hapfelmeier.

**Writing – original draft:** Johannes Ettl, Evelyn Klein.

**Writing – review & editing:** Johannes Ettl, Evelyn Klein, Alexander Hapfelmeier, Kirsten Grosse Lackmann, Stefan Paepke, Christoph Petry, Katja Specht, Laura Wolff, Heinz Höfler, Marion Kiechle.

**References**

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, et al. (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353: 1784–1792. https://doi.org/10.1056/NEJMoa050518 PMID: 16251534

2. Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, et al. (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-
term outcome among 100,000 women in 123 randomised trials. Lancet 379: 432–444. https://doi.org/10.1016/S0140-6736(11)61625-5 PMID: 22152853

3. Duffy MJ, Duggan C (2004) The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 37: 541–548. https://doi.org/10.1016/j.clinbiochem.2004.05.013 PMID: 15234235

4. Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, et al. (1988) Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 62: 531–533. PMID: 3134120

5. Janicke F, Schmitt M, Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost 17: 303–312. https://doi.org/10.1055/s-2007-1002624 PMID: 1796300

6. Duffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M (2013) uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res 16: 428. https://doi.org/10.1186/s13058-014-0428-4 PMID: 25677449

7. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101: 1446–1452. https://doi.org/10.1093/jnci/djp335 PMID: 19815849

8. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, et al. (2013) Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 49: 1825–1835. https://doi.org/10.1016/j.ejca.2013.01.007 PMID: 23490655

9. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, et al. (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 94: 116–128. PMID: 11792750

10. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25: 5287–5312. https://doi.org/10.1200/JCO.2007.14.2364 PMID: 17954709

11. AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2015. http://www.ago-online.de

12. Goldhirsch A, Click JH, Gelber RD, Coates AS, Thomlmann B, et al. (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16: 1569–1583. https://doi.org/10.1093/annonc/mdi326 PMID: 16148022

13. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747–752. https://doi.org/10.1038/35021093 PMID: 10963602

14. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874. https://doi.org/10.1073/pnas.191367098 PMID: 11553815

15. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Grant M, et al. (2015) -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26: 1533–1546. https://doi.org/10.1093/annonc/mdv221 PMID: 25939896

16. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzial F, et al. (2011) A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17: 6012–6020. https://doi.org/10.1158/1078-0432.CCR-11-0926 PMID: 21807638

17. Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, et al. (2013) The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 109: 2959–2964. https://doi.org/10.1038/bjc.2013.671 PMID: 24157828

18. Fitzial F, Filipits M, Rudas M, Greil R, Dietze O, et al. (2015) The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positiv, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. Br J Cancer 112: 1405–1410. https://doi.org/10.1038/bjc.2015.98 PMID: 25867274

19. Kreienberg R, Albert US, Follmann M, Kopp IB, Kuhn T, et al. (2013) Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version—AWMF Registry No.: 032-045O L AWMF-Register-Nummer: 032-045OL—Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd 73: 556–583. https://doi.org/10.1055/s-0032-1288889 PMID: 24771925

20. Muller BM, Keil E, Lehmann A, Winzer KJ, Richter-Ehrenstein C, et al. (2013) The EndoPredict Gene-Expression Assay in Clinical Practice—Performance and Impact on Clinical Decisions. PLoS One 8: e68262. https://doi.org/10.1371/journal.pone.0068262 PMID: 23823692
21. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, et al. (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 93: 913–920. PMID: 11416112

22. R Core Team (2015). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/.

23. Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, et al. (2015) Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics 33: 179–190. https://doi.org/10.1007/s40273-014-0227-x PMID: 25404424

24. Kolben T, Augustin D, Armbrust R, Kolben TM, Degenhardt T, et al. (2016) Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer. Breast Cancer Res Treat 155: 109–115. https://doi.org/10.1007/s10549-015-3653-3 PMID: 26643086

25. Schlake G, Kronenwett R, Tiecke F, et al. EndoPredict-based treatment decision can reduce chemotherapy usage in ER+, HER2- breast cancer. Presented at 14th St. Gallen International Breast Cancer Conference 2015

26. Harbeck N, Kates RE, Schmitt M (2002) Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 20: 1000–1007. https://doi.org/10.1200/JCO.2002.20.4.1000 PMID: 11844823

27. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, et al. (1998) Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13: 893–906. PMID: 9772277

28. Varga Z, Sinn P, Fritzschke F, von Hochstetter A, Noske A, et al. (2013) Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One 8: e58483. https://doi.org/10.1371/journal.pone.0058483 PMID: 23905515

29. Venat-Bouvet L, Fermeaux V, Leobon S, Saidi N, Monteil J, et al. (2014) Adjuvant chemotherapy in node-negative breast cancer: UPA/PAI-1 determinations for 163 cases. Anticancer Res 34: 1213–1217. PMID: 24596362